Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) acro

PROS Holdings, Inc. (PRO) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2025Q3
while the company shows improving liquidity with a current ratio of 1.56, the persistent negative net margin of -4.6% and high debt-to-equity risks warrant a cautious wait-and-see approach.
PROS Holdings, Inc. (PRO) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
PROS Holdings, Inc. (PRO) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q4 2025Latest | Oct 27, 2025 | $0.22vs $0.17+29.4% | $92Mvs $95M-3.5% |
| Q3 2025 | Jul 31, 2025 | $0.13vs $0.07+85.7% | $89Mvs $91M-2.7% |
| Q2 2025 | May 1, 2025 | $0.13vs $0.13+0.0% | $86Mvs $86M+0.8% |
| Q1 2025 | Feb 6, 2025 | $0.16vs $0.12+33.3% | $85Mvs $85M+0.3% |
Recent stock market news and headlines for PROS Holdings, Inc. (PRO)
Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) acro

Key metrics vs top competitors for PROS Holdings, Inc. (PRO)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $23.25 | $1.12B | -54.07 | 8.78% | -6.2% | — | — | |
| $179.42 | $6.46B | 46.24 | 19.72% | 15.27% | 30.9% | — | |
| $118.84 | $6.36B | 29.56 | 13.74% | 14.94% | 22.36% | — | |
| $60.93 | $2.28B | 24.77 | 17.83% | 11.92% | 9.45% | — | |
| $157.55 | $5.55B | 28.96 | 10.13% | 29.41% | 37.15% | — | |
| $18.76 | $539.62M | 14.43 | 13.83% | 13.89% | 90.79% | — |
PROS Holdings, Inc. (PRO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
PROS Holdings, Inc. (PRO) SEC filings — annual & quarterly reports (10-K, 10-Q)
Dec 9, 2025·SEC
Dec 5, 2025·SEC
Nov 26, 2025·SEC
Get notified when PRO posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
PROS Holdings, Inc. (PRO) stock FAQ — growth, dividends, profitability & financials explained
PROS Holdings, Inc. (PRO) reported $351.7M in revenue for fiscal year 2024. This represents a 901% increase from $35.1M in 2005.
PROS Holdings, Inc. (PRO) grew revenue by 8.8% over the past year. This is steady growth.
PROS Holdings, Inc. (PRO) reported a net loss of $11.7M for fiscal year 2024.
PROS Holdings, Inc. (PRO) generated $38.6M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.